MBX — MBX Biosciences, Inc. Common Stock stock price, charts and financials

QT67MBX Biosciences, Inc. Common Stock

MBX Biosciences, Inc. Common Stock (NASDAQ: MBX) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
66.15
-1.67-2.46%
OverviewShort InterestFilings
MBXQT67MBX Biosciences, Inc. Common Stock·NASDAQ
66.15-2.46%
TA
Loading chart...
Signal & projected range
Insider open-market saleHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
QURE-0.78%$46.06NAMS+0.07%$27.98ARQT+2.49%$25.92TNGX+2.22%$27.67GPCR+1.25%$53.80ALMS-0.25%$27.53RLAY+0.86%$19.94GRAL+7.71%$74.84
Snapshot
Index-P/E-EPS (ttm)-Insider Own-Shs Outstand47.60MPerf Week2.87%
Market Cap3.23BForward P/E-EPS next Y-3.65Insider Trans-0.09%Shs Float20.70MPerf Month3.21%
Enterprise Value3.18BPEG4.85EPS next Q-Inst Own-Short Float12.14%Perf Quarter95.39%
Income-103.94MP/S0.00EPS this Y-Inst Trans-Short Ratio7.11Perf Half Y88.13%
Sales0.00P/B7.90EPS next Y-31.05%ROA-23.93%Short Interest5.78MPerf YTD115.03%
Book/sh-P/C-EPS next 5Y-ROE-26.01%52W High70.85 -6.64%Perf Year481.15%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-28.56%52W Low9.39 604.26%Perf 3Y-
Dividend Est.-EV/EBITDA-Sales past 3/5Y-Gross Margin0.00%Volatility7.43% 7.84%Perf 5Y-
Dividend TTM-EV/Sales0.00EPS Y/Y TTM-19.46%Oper. Margin0.00%ATR (14)4.64Perf 10Y-
Dividend Ex-Date-Quick Ratio18.08Sales Y/Y TTM-Profit Margin0.00%RSI (14)62.29Recom2.00
Dividend Gr. 3/5Y-Current Ratio18.08EPS Q/Q28.17%SMA207.82%Beta1.42Target Price71.50
Payout0.00%Debt/Eq0.01Sales Q/Q-SMA5031.81%Rel Volume0.64Prev Close67.82
Employees63LT Debt/Eq0.00EarningsNov 05SMA20086.84%Avg Volume853.72KPrice66.15
IPO DateSep 13, 2024Option/ShortYes / YesEPS/Sales Surpr.12.77% -Net Debt/EBITDA0.47Volume545,470Change-2.46%
Analyst Ratings
DateActionAnalystRatingTarget
Jul-23-26ReiteratedUBS$60 → $90
May-12-26ReiteratedStifel Nicolaus$50 → $56
May-12-26ReiteratedBarclaysOverweight$66 → $70
May-11-26ReiteratedTruist SecuritiesBuy$50 → $70
Mar-09-26ReiteratedTruist Financial$50
Jan-27-26InitiatedBarclaysOverweight$66
Jan-16-26ReiteratedGuggenheimBuy$44 → $88
Jan-07-26ReiteratedUBS$60
Dec-19-25ReiteratedStifel Nicolaus$45 → $50
Dec-04-25InitiatedGoldman SachsSell$18
Latest News
Aug-06-26
Aug-06-2608:05AM
MBX Biosciences Q2 EPS $(0.78) Misses $(0.63) EstimateBenzinga
Jul-31-26
Jul-31-2603:45AM
MBX Biosciences (NASDAQ:MBX) Reaches New 12-Month High After Analyst Upgradedefenseworld.net
Jul-29-26
Jul-29-2611:50AM
Mizuho Maintains Outperform on MBX Biosciences, Raises Price Target to $91Benzinga
Jul-26-26
Jul-26-2602:02AM
MBX Biosciences (NASDAQ:MBX) Hits New 12-Month High – Here’s Whydefenseworld.net
Jul-17-26
Jul-17-2610:09AM
ManpowerGroup Posts Upbeat Q2 Earnings, Joins Docebo, Zentalis Pharmaceuticals And Other Big Stocks Moving Higher On FridayBenzinga
05:49AM
Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) vs. MBX Biosciences (NASDAQ:MBX) Critical Surveydefenseworld.net
Jul-13-26
Jul-13-2605:05PM
12 Health Care Stocks Moving In Monday's After-Market SessionBenzinga
04:15PM
MBX Biosciences Announces Executive Leadership Transition to Support the Company's Next Phase of Growthglobenewswire.com
Jul-06-26
Jul-06-2608:38AM
MBX Biosciences: Weekly PTH, Monthly Obesity, Multi-Year Upside (Initiating Buy)SeekingAlpha
Jun-12-26
Jun-12-2602:32PM
MBX Biosciences, Inc. (MBX) Discusses One-Year Data From Phase II Open-Label Extension Study of Once-Weekly Canvuparatide TranscriptSeekingAlpha
12:30PM
These stocks that are showing activity before the opening bell on Friday.ChartMill
10:43AM
MBX Biosciences Highlights Sustained Calcium Control In Rare DiseaseBenzinga
09:43AM
MBX Biosciences, Inc. (MBX) Discusses One-Year Data From Phase II Open-Label Extension Study of Once-Weekly Canvuparatide - SlideshowSeekingAlpha
08:05AM
12 Health Care Stocks Moving In Friday's Pre-Market SessionBenzinga
08:02AM
Lennar Reports Mixed Q2 Results, Joins Adobe And Other Big Stocks Moving Lower In Friday's Pre-Market SessionBenzinga
Company

MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism. The company is also progressing with MBX 1416, a prolonged-action glucagon-like peptide-1 (GLP-1) receptor antagonist, which is undergoing Phase 1 clinical assessment. The aim of this therapy is to address post-bariatric hypoglycemia, a persistent complication often seen after weight-loss surgery. Furthermore, MBX Biosciences is developing MBX 4291, a key candidate for obesity treatment. This highly potent and long-acting prodrug functions as a co-agonist for both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is currently in investigational new drug (IND)-enabling studies, with the intention of treating obesity and its associated health issues. Founded in 2018, the company's operations are headquartered in Carmel, Indiana.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
Total Revenue
000—
Cost of Goods Sold Incl. D&A
000—
Gross Profit
000—
Selling, General and Administrative Excl. Other19117—
Research and Development795729—
Other Operating Expense00-1—
Operating Income-98-68-35—
Interest Expense
000—
Unusual Expense
————
Non-Operating Income (Expense)1163—
Net Income Before Taxes-87-62-33—
Income Taxes
000—
Consolidated Net Income-87-62-33—
Net Income From Continuing Operations-87-62-33—
Net Income-87-62-33—
EPS (Recurring)-2.38-1.85-1.02—
EPS (Basic, Before Extraordinaries)-2.38-1.85-1.02—
EPS (Diluted)-2.38-1.85-1.02—
EBITDA-87-62-32—
Other After Tax Adjustments
————
Stock Option Compensation Expense
————
Price To Earnings Ratio
————
Price To Sales Ratio
————
Gross Margin
————
Operating Margin
————
Net Margin
————
Shares Outstanding373332—
Market Capitalization1,167608——
Operating Lease Expense
————
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$79.85$60.03$40.22$20.40$0.58● Close Price0.00M3.00M6.00M9.00M12.00MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Azoulay SalomonChief Medical OfficerAug 04 '26Sale65.7737024,33514,399Aug 05
Azoulay SalomonChief Medical OfficerMay 08 '26Option Exercise11.65140,0061,630,696194,540May 11
Azoulay SalomonChief Medical OfficerMay 08 '26Sale38.3670,0032,685,51514,769May 11
Hawryluk P. KentPresident & CEOMay 06 '26Sale29.5460717,931727,667May 08
Azoulay SalomonChief Medical OfficerMay 06 '26Sale29.542316,82414,769May 08
Hawryluk P. KentPresident & CEOMar 13 '26Buy28.4118,500525,663486,777Mar 16
Hawryluk P. KentPresident & CEOFeb 26 '26Option Exercise16.0028,768460,288728,274Feb 27
Hawryluk P. KentPresident & CEOOct 24 '25Option Exercise3.25182,859594,292664,256Oct 28
Hawryluk P. KentPresident & CEOOct 20 '25Buy13.6420,000272,790468,277Oct 21
Hoerter Steven L.DirectorOct 17 '25Buy13.2520,000264,98420,000Oct 20
Heron Patrick Jdirector, 10 percent owner:Sep 26 '25Buy18.00666,66611,999,9885,219,440Sep 30
Pescovitz Ora H.DirectorApr 08 '25Buy5.897,69345,31224,329Apr 10
ORBIMED ADVISORS LLCdirector, 10 percent owner:Feb 18 '25Buy10.84143,1701,551,9633,255,000Feb 19
GORDON CARL Ldirector, 10 percent owner:Feb 18 '25Buy10.84143,1701,551,9633,255,000Feb 19
ORBIMED ADVISORS LLCdirector, 10 percent owner:Feb 14 '25Buy9.8747,502468,7933,205,930Feb 19
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.